Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Exelixis Inc (NASDAQ:EXEL)

19.35
Delayed Data
As of May 26
 -0.22 / -1.12%
Today’s Change
6.16
Today|||52-Week Range
24.85
+29.78%
Year-to-Date
Biotech Movers: Immunomedics, Aerie, Exelixis
May 26 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close19.57
Today’s open19.55
Day’s range19.19 - 19.72
Volume2,378,096
Average volume (3 months)4,255,697
Market cap$5.7B
Dividend yield--
Data as of 4:00pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)+65.43%
Earnings growth (this year)+165.08%
Earnings growth (next 5 years)+46.00%
Revenue growth (last year)+415.05%
P/E ratio645.0
Price/Sales19.51
Price/Book63.52

Competitors

 Today’s
change
Today’s
% change
ICLRICON PLC+1.76+1.96%
PRAHPRA Health Sciences ...+0.17+0.24%
CRLCharles River Labora...+0.34+0.37%
PRXLPAREXEL Internationa...+0.68+0.86%
Data as of 4:02pm ET, 05/26/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$0.04
Annual revenue (last year)$191.5M
Annual profit (last year)-$70.2M
Net profit margin-36.68%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Executive VP, Chief Financial &
Accounting Officer
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts